IDXX
IDEXX Laboratories, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +5.0% ·
share flow -0.5% ·
net new positions 0.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 471.56K | $245.77M | n/a | n/a |
| Q2 2026 | 168 | 0 | 55.55M | $29.26B | +7 | −6 |
| Q1 2026 | 170 | +1 | 53.67M | $30.16B | +5 | −5 |
| Q4 2025 | 168 | +2 | 58.18M | $39.32B | +3 | n/a |
| Q3 2025 | 21 | +1 | 29.88M | $19.09B | +1 | −1 |
| Q2 2025 | 18 | 0 | 26.38M | $14.14B | +1 | −1 |
| Q1 2025 | 15 | -2 | 9.43M | $3.96B | n/a | −2 |
| Q4 2024 | 17 | -1 | 9.47M | $3.92B | n/a | −1 |
| Q3 2024 | 17 | +1 | 5.70M | $2.88B | +1 | n/a |
| Q2 2024 | 16 | n/a | 5.12M | $2.49B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.96M | +0.9% | $6.36B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 8.21M | -2.0% | $5.24B | 0.1% | ▼ Trim | 2 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (passive) | 3.52M | -1.0% | $2.25B | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.50M | +1.4% | $1.59B | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | JPMorgan Chase ✦ | 1.74M | n/a | $1.11B | 0.0% | n/c | 1 | SEC ↗ ×34 |
| 6 | Morgan Stanley ✦ | 1.62M | n/a | $1.04B | 0.1% | n/c | 1 | SEC ↗ ×21 |
| 7 | Goldman Sachs Group ✦ | 711.94K | n/a | $454.85M | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 8 | T. Rowe Price ✦ | 694.21K | +29.5% | $443.52M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Fidelity (FMR) ✦ | 233.05K | -13.7% | $148.89M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 10 | Wellington Management ✦ | 186.38K | -0.9% | $119.08M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 11 | Arrowstreet Capital ✦ | 185.09K | -10.2% | $118.25M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 135.15K | -39.5% | $85.40M | 0.1% | ▼ Trim | 6 | SEC ↗ ×5 |
| 13 | Millennium Management ✦ | 63.52K | -19.4% | $40.58M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 48.64K | +40.4% | $31.08M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 35.67K | -39.8% | $22.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 27.58K | -36.4% | $17.62M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Two Sigma Investments ✦ | 9.70K | 0.0% | $6.20M | 0.0% | Held | 6 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 7.40K | +182.1% | $4.73M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 500 | -97.5% | $319,445 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Harris Associates (Oakmark) ✦ | 455 | New | $290,695 | 0.0% | New | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 353 | -98.4% | $225,528 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Harris Associates (Oakmark) | $290,695 | 0.0% |
Exited
| Norges Bank | $221.95M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,302 holders, 70.72M shares, $38.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.20K sh · $1.17M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology